Members of the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee recently issued a general report on cases where Syfovre eye injuries decreased vision for patients after Syfovre treatments. In summary, this report revealed that at least 13 patients had Syfovre retinal-related vision loss in … [Read more...]
2024 BIA-ALCL Report by the American Association of Plastic Surgeons
In March 2017 we wrote this article, "Breast Implants Linked to Rare Lymphoma Blood Cancer", which started our coverage of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) related to textured breast implants. Seven years later, we point out an article published on February 27, 2024, by the Plastic and Reconstructive Surgery … [Read more...]
Wegovy / Rybelsus / Ozempic DVT Blood Clots Side Effects Cases
Wegovy, Rybelsus, and Ozempic DVT blood clots side effects have not received as much attention as adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis. Ozempic, Wegovy, and Rybelsus are three popular GLP-1 receptor agonists containing semaglutide that are increasingly used as … [Read more...]
Pegargiminase Confers Survival Benefit in Nonepithelioid Pleural Mesothelioma
Adding [ new treatment drug ] pegargiminase to standard chemotherapy can improve outcomes in patients with chemotherapy-naïve, nonepithelioid pleural mesothelioma, according to research published in JAMA Oncology. [Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural … [Read more...]
Gastroparesis Cases Involving Ozempic, Rybelsus, Wegovy, and Trulicity as Weight-loss Drugs
We are handling gastroparesis cases involving Ozempic, Rybelsus, Wegovy, and Trulicity as drug injury lawsuits filed against the responsible pharmaceutical companies. In this piece, we point out two medical journal articles that present a few gastroparesis cases involving the use of semaglutide (Ozempic, Rybelsus, Wegovy) or dulaglutide … [Read more...]
FDA Fast Tracks UV1, Ipilimumab, and Nivolumab in Malignant Mesothelioma
The FDA has granted a fast track designation to the combination of UV1 with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma. This regulatory decision is supported by findings from the phase 2 NIPU trial which is evaluating UV1 in patients with unresectable malignant pleural mesothelioma. … [Read more...]
A Complete Response to Pembrolizumab in Malignant Peritoneal Mesothelioma: A Case Report
Abstract: Malignant peritoneal mesothelioma (MPeM) is a rare cancer of the peritoneum with a poor prognosis and nonspecific clinical course. We discuss a case of MPeM in a 59-year-old male who presented with abdominal pain and distension, without any known previous asbestos exposure. The diagnosis was made after a second biopsy finally confirmed … [Read more...]
Prolia Drug Label Change: Warning for Severe Hypocalcemia in Patients With Chronic Kidney Disease
A January 2024 Prolia drug label change that added a “Black-Box” warning for the “new” Prolia hypocalcemia side effect was announced through this Drug Safety Communication “FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab).” This … [Read more...]
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial
Introduction: Treatment of homologous recombination repair deficient (HRD)-tumours with PARP inhibitors has the potential to further increase tumour immunogenicity, suggesting a synergistic effect with immunotherapy. Here we present the preliminary results of niraparib in combination with dostarlimab for pleural mesothelioma (PM) or non-small cell … [Read more...]
PFAS Update: EPA PFAS CERCLA Designation Takes Effect in 2024
GenX Cases Involving Certain Cancers Filed as PFAS Lawsuits by Individuals May Benefit The United States Environmental Protection Agency (EPA) has designated certain per- and polyfluoroalkyl substances (PFAS) as hazardous substances under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Specifically, the … [Read more...]
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 22
- Next Page »